Iovance Q4 revenue rises on Amtagvi demand

Iovance Biotherapeutics

24/02/2026 12:15

Overview

Biotechnology firm's Q4 revenue grew 30%, driven by Amtagvi demand

Net loss for Q4 missed analyst expectations

Operating loss for Q4 beat analyst estimates

Outlook

Company expects operational improvements in operating expenses and margins in 2026 and 2027

Iovance anticipates UK and Australia approvals for Amtagvi in 1H26

Company plans EMA resubmission for Amtagvi in 2026

Result Drivers

AMTAGVI DEMAND - Quarterly revenue growth driven by increasing demand for Amtagvi, with U.S. revenue reaching ~$65 mln

GROSS MARGIN IMPROVEMENT - Gross margin increased to 50% due to cost optimization and operational improvements

EXPANDED ACCESS - Growing network of U.S. authorized treatment centers expanded patient access, contributing to Amtagvi's growth

Company press release: ID:nGNX3bgbpN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$86.77 mln
Q4 Net Income
Miss
-$71.90 mln
-$68.83 mln (8 Analysts)
Q4 Operating Income
Beat
-$73.46 mln
-$77.39 mln (8 Analysts)
Q4 Pretax Profit
Miss
-$71.72 mln
-$70.61 mln (8 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $10.00, about 246% above its February 23 closing price of $2.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)